Vertex Pharmaceuticals has seen its fair value estimate inch up from about $480 to roughly $485 per share as analysts refresh their models around a more constructive long term growth narrative.

Investing.com - Morgan Stanley upgraded Vertex Pharmaceuticals (NASDAQ:VRTX) from Equalweight to Overweight on Wednesday, raising its price target to $516.00 from $438.00. The new target represents ...

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 6.2% in the afternoon session after Morgan Stanley upgraded its rating on the stock to "Overweight" from "Equal-Weight" and ...

Bruker Corporation today announced the launch of the VERTEX NEO Ultra, its most advanced and versatile benchtop vacuum Fourier-Transform Infrared (FT-IR) spectrometer. Building on the VERTEX NEO ...

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid pain medicine Journavx and gene therapy Casgevy. Vertex clocked 11% growth ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A former executive at Microsoft ...

Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three ...

Vertex Pharmaceuticals Incorporated is downgraded from Buy to Hold due to mounting headwinds and pipeline uncertainties. Vertex faces pressure from potential U.S. drug pricing reforms and tariffs, ...

Vertex Pharmaceuticals (VRTX) plunged after Q2 earnings and is now down 21% over the past year. The company has historically had a strong R&D pipeline and has consistently been a winner, but the ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Vertex Pharmaceuticals said Monday that ...